TargetBeta
MS4A1
membrane spanning 4-domains A1 · also B1, Bp35, FMC7, CD20 · CD molecules
24 programs in company-led studies act on MS4A1, from 18 companies: 9 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (20 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 17518 running | – | NCIt |
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 4213 running | – | NCIt |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 4211 running | – | ChEMBL |
| epcoritamabrule | Genmab | phase 3 | 1312 running | CD3E | ChEMBL |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 139 running | CD3E | ChEMBL |
| ublituximabrule | TG Therapeutics | phase 3 | 237 running | – | NCIt |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 147 running | CD3E | ChEMBL |
| Anti-CD20 Monoclonal Antibody MIL62rule | Beijing Mabworks Biotech | phase 3 | 107 running | – | NCIt |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 86 running | CD3E | ChEMBL |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 54 running | CD3E | the company's pipeline |
| zuberitamabrule | BioRay Pharmaceutical | phase 3 | 32 running | – | NCIt |
| rondecabtagene autoleucelrule | Lyell Immunopharma | phase 3 | 22 running | CD19 | NCIt |
| zamtocabtagene autoleucelrule | Miltenyi Biomedicine | phase 2 | 87 running | CD19, CD4, CD8A | NCIt |
| Autologous Anti-CD19/CD20 CAR-T Cells KITE-363rule | Gilead Sciences | phase 2 | 33 running | CD19 | NCIt |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 22 running | CD3E, CD8A | a judged reading |
| GSK5926371 | GlaxoSmithKline | phase 2 | 22 running | CD19, CD3E | the company's pipeline |
| prizloncabtagene autoleucelrule | AbelZeta | phase 2 | 22 running | CD19 | NCIt |
| Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203rule | AvenCell Therapeutics | phase 2 | 11 running | CD19 | NCIt |
| CT204V-CD19 × CD20rule | AstraZeneca | phase 2 | 11 running | CD19 | the studies' text |
| REGN9220rule | Regeneron Pharmaceuticals | phase 2 | 11 running | CD22, CD3E | the studies' text |
| Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543rule | Johnson & Johnson | phase 1 | 33 running | CD3E | NCIt |
| Anti-CD20 Bispecific Antibody DR-0201 | Sanofi | phase 1 | 32 running | – | the company's pipeline |
| prulacabtagene leucelrule | Adicet Therapeutics | phase 1 | 22 running | – | NCIt |
| HB2198rule | Hinge Bio | phase 1 | 11 running | CD19 | the studies' text |
Conditions their studies are in
- Lymphoma, Large B-Cell, Diffuse, 11 programs
- Lupus Nephritis, 9 programs
- Lymphoma, B-Cell, 9 programs
- Lymphoma, Non-Hodgkin, 8 programs
- Lymphoma, Follicular, 7 programs
- Leukemia, Lymphocytic, Chronic, B-Cell, 5 programs
- Lupus Erythematosus, Systemic, 5 programs
- Arthritis, Rheumatoid, 3 programs
- Multiple Sclerosis, 3 programs
- Glomerulonephritis, Membranous, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026obinutuzumab · Hoffmann-La Roche · phase 4 · NCT04895436
- Dec 2026prulacabtagene leucel · Adicet Therapeutics · phase 1 · NCT06375993
- Dec 31, 2026zamtocabtagene autoleucel · Miltenyi Biomedicine · phase 2 · NCT04792489
- Jan 21, 2027ublituximab · TG Therapeutics · phase 3 · NCT05877963
- Feb 2027ocrelizumab · Hoffmann-La Roche · phase 4 · NCT05906992
- Feb 13, 2027Rituximab · Hoffmann-La Roche · phase 4 · NCT04224493
- Mar 2027epcoritamab · Genmab · phase 3 · NCT05451810
- Mar 22, 2027glofitamab · Hoffmann-La Roche · phase 3 · NCT06624085
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.